SICKLEKAN CIC

Company Registration Number:
10371535 (England and Wales)

Unaudited statutory accounts for the year ended 30 September 2024

Period of accounts

Start date: 1 October 2023

End date: 30 September 2024

SICKLEKAN CIC

Contents of the Financial Statements

for the Period Ended 30 September 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

SICKLEKAN CIC

Directors' report period ended 30 September 2024

The directors present their report with the financial statements of the company for the period ended 30 September 2024

Principal activities of the company

To Provide Support and guidance for children parents and families affected by sickle cell disease, while enabling a safe environment for sickle cell disease patients, to share their experiences stigma free. To raise awareness for sickle cell disease while encouraging more black blood donors to donate blood for sickle cell patients needing blood transfusions for a better quality of life



Directors

The director shown below has held office during the whole of the period from
1 October 2023 to 30 September 2024

Kehinde Salami


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
25 September 2025

And signed on behalf of the board by:
Name: Kehinde Salami
Status: Director

SICKLEKAN CIC

Profit And Loss Account

for the Period Ended 30 September 2024

2024 2023


£

£
Turnover: 6,700 3,500
Cost of sales: ( 2,300 ) ( 1,400 )
Gross profit(or loss): 4,400 2,100
Administrative expenses: ( 380 ) ( 115 )
Other operating income: 1,275 750
Operating profit(or loss): 5,295 2,735
Profit(or loss) before tax: 5,295 2,735
Profit(or loss) for the financial year: 5,295 2,735

SICKLEKAN CIC

Balance sheet

As at 30 September 2024

Notes 2024 2023


£

£
Fixed assets
Intangible assets: 3 1,780 1,250
Tangible assets:   0 0
Investments:   0 0
Total fixed assets: 1,780 1,250
Current assets
Stocks:   0
Debtors:   0
Cash at bank and in hand: 3,895 1,485
Investments:   0
Total current assets: 3,895 1,485
Prepayments and accrued income: 0 0
Creditors: amounts falling due within one year:   0 0
Net current assets (liabilities): 3,895 1,485
Total assets less current liabilities: 5,675 2,735
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: 0 0
Accruals and deferred income: 0 0
Total net assets (liabilities): 5,675 2,735
Capital and reserves
Called up share capital: 380 250
Share premium account: 0 0
Other reserves: 0 0
Profit and loss account: 5,295 2,485
Total Shareholders' funds: 5,675 2,735

The notes form part of these financial statements

SICKLEKAN CIC

Balance sheet statements

For the year ending 30 September 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 25 September 2025
and signed on behalf of the board by:

Name: Kehinde Salami
Status: Director

The notes form part of these financial statements

SICKLEKAN CIC

Notes to the Financial Statements

for the Period Ended 30 September 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

SICKLEKAN CIC

Notes to the Financial Statements

for the Period Ended 30 September 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 2 2

SICKLEKAN CIC

Notes to the Financial Statements

for the Period Ended 30 September 2024

3. Intangible assets

Goodwill Other Total
Cost £ £ £
At 1 October 2023 0 1,250 1,250
Additions 0 530 530
Disposals 0 0 0
Revaluations 0 0 0
Transfers 0 0 0
At 30 September 2024 0 1,780 1,780
Amortisation
At 1 October 2023 0 0 0
Charge for year 0 0
On disposals 0 0
Other adjustments 0 0
At 30 September 2024 0 0 0
Net book value
At 30 September 2024 0 1,780 1,780
At 30 September 2023 0 1,250 1,250

COMMUNITY INTEREST ANNUAL REPORT

SICKLEKAN CIC

Company Number: 10371535 (England and Wales)

Year Ending: 30 September 2024

Company activities and impact

The Charity Has provided support in the following areas To provide support for children, parents and family impacted by sickle cell disease. Supporting local businesses, hospitals and businesses as well as educational establishments in regards to awareness support, for sickle cell patients within their care. Raising awareness to ethnically matched blood donors needed for sickle cell patients needing blood transfusions for a better quality of life. Providing those with sickle cell disease a voice to talk about living with the condition without stigma or prejudice.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
25 September 2025

And signed on behalf of the board by:
Name: Kehinde Salami
Status: Director